Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]

Christopher G. Willett, Yves Boucher, Dan G. Duda, Emmanuelle Di Tomaso, Lance L. Munn, Ricky T. Tong, Sergey V. Kozin, Lucine Petit, Rakesh K. Jain, Daniel C. Chung, Dushyant V. Sahani, Sanjeeva P. Kalva, Kenneth S. Cohen, David T. Scadden, Alan J. Fischman, Jeffrey W. Clark, David P. Ryan, Andrew X. Zhu, Lawrence S. Blaszkowsky, Paul C. ShellitoMari Mino-Kenudson, Gregory Y. Lauwers

Research output: Contribution to journalLetter

350 Scopus citations
Original languageEnglish (US)
Pages (from-to)8136-8139
Number of pages4
JournalJournal of Clinical Oncology
Volume23
Issue number31
DOIs
StatePublished - Dec 1 2005

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Willett, C. G., Boucher, Y., Duda, D. G., Di Tomaso, E., Munn, L. L., Tong, R. T., Kozin, S. V., Petit, L., Jain, R. K., Chung, D. C., Sahani, D. V., Kalva, S. P., Cohen, K. S., Scadden, D. T., Fischman, A. J., Clark, J. W., Ryan, D. P., Zhu, A. X., Blaszkowsky, L. S., ... Lauwers, G. Y. (2005). Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients [18]. Journal of Clinical Oncology, 23(31), 8136-8139. https://doi.org/10.1200/JCO.2005.02.5635